🧪
hypothesis

Combinatorial Epigenetic Therapy Targeting REST Convergence Hub

Hypothesis

Combinatorial Epigenetic Therapy Targeting REST Convergence Hub

Combinatorial Epigenetic Therapy Targeting REST Convergence Hub.
🧬 REST pathway + combinatorial HDAC/DNMT inhibition🩺 neurodegeneration🎯 Composite 42%💱 $0.48▲15.1%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 4 support 5 oppose
⚠ Missing Evidence⚠ Thin Description Senate Quality Gates →
Mechanistic 0.45 (15%) Evidence 0.38 (15%) Novelty 0.72 (12%) Feasibility 0.28 (12%) Impact 0.52 (12%) Druggability 0.32 (10%) Safety 0.30 (8%) Competition 0.45 (6%) Data Avail. 0.42 (5%) Reproducible 0.35 (5%) KG Connect 0.50 (8%) 0.420 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite42%

🧪 Overview

Combinatorial Epigenetic Therapy Targeting REST Convergence Hub

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["REST/NRSF Transcriptional Repressor<br/>Neuronal Gene Silencing Factor"]
    B["GABAergic and Synaptic Gene Suppression<br/>Non-neuronal Cell Identity Maintenance"]
    C["Tau and ATXN2 Modulation<br/>Neurodegeneration Linkage"]
    D["REST Deficiency in Aging<br/>Neurotoxic Gene Derepression"]
    E["Neuronal Identity Loss<br/>Synaptic Vulnerability"]
    F["REST Activating Compounds<br/>Neuroprotective Target Validation"]
    G["AD and FTD Mechanisms<br/>REST-Dependent Protection Failure"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    F --> G
    style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
    style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style F fill:#1b5e20,stroke:#81c784,color:#81c784

⚖️ Evidence

⚖️ Evidence Matrix4 supports5 contradicts
Supports
REST is downregulated in AD, PD, and ALS, correlating with increased neuronal vulnerability
PMID:24439122
Supports
Combined HDAC/DNMT inhibition shows synergistic transcriptional reactivation in cancer models
PMID:26707847
Supports
Valproate has been safely used in clinical trials for neurological conditions with acceptable CNS penetration
PMID:28161408
Supports
REST target gene BDNF shows hypermethylation in neurodegenerative conditions
PMID:28446489
Contradicts
Combinatorial toxicity - combining HDAC + DNMT inhibitors increases adverse effect risk with narrow therapeutic indices
PMID:29990389
Contradicts
REST has context-dependent functions - protective in excitotoxicity but potentially detrimental in other contexts
PMID:24439122
Contradicts
Valproate carries black box warnings for hepatotoxicity and teratogenicity
PMID:29990389
Contradicts
REST downregulation may be a protective response allowing neuronal stress adaptation
PMID:24439122
Contradicts
Cancer synergy data may not apply to post-mitotic neurons where cell cycle re-entry is harmful
PMID:26707847
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — REST

No curated PDB or AlphaFold mapping for REST yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for REST pathway + combinatorial HDAC →

No DepMap CRISPR Chronos data found for REST pathway + combinatorial HDAC.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.7%
Volatility
Low
0.0062
Events (7d)
2
Price History
▲15.1%

💾 Resource Usage

LLM Tokens
34,738
$0.1042
Total Cost
$0.1042

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF 3-month-old 5xFAD mice receive 8-week intraperitoneal treatment with SAHA (10 mg/kg) + 5-aza-dC (0.5 mg/kg) thrice weekly, THEN spatial memory retention will improve by ≥25% in Morris water maze (l≥25% reduction in platform search latency during probe trial and ≥20% reduction in cortical Aβ42 ELISA levels versus vehicle.— no observation —pending0.55
IF primary cortical neurons from a 5xFAD mouse model are treated for 7 days with combinatorial SAHA (1 µM) + 5-aza-2'-deoxycytidine (1 µM), THEN REST target gene expression (Bdnf exon IV, Ngn1, Syn1) ≥30% upregulation of REST target genes by qRT-PCR with p<0.05, alongside maintained cell viability (>90% by Calcein-AM).— no observation —pending0.65
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF primary cortical neurons from a 5xFAD mouse model are treated for 7 days with combinatorial SAHA (1 µM) + 5-aza-2'-deoxycytidine (1 µM), THEN REST target gene expression (Bdnf exon IV, Ngn1, Syn1) will increase ≥30% compared to vehicle or single-agent controls.
Predicted outcome: ≥30% upregulation of REST target genes by qRT-PCR with p<0.05, alongside maintained cell viability (>90% by Calcein-AM).
Falsification: No significant change in REST target gene expression (<15% change, p>0.05) or cytotoxicity (>20% decrease in viability) compared to vehicle controls.
pendingconf 55%
IF 3-month-old 5xFAD mice receive 8-week intraperitoneal treatment with SAHA (10 mg/kg) + 5-aza-dC (0.5 mg/kg) thrice weekly, THEN spatial memory retention will improve by ≥25% in Morris water maze (latency reduction) and cortical amyloid-β burden will decrease ≥20% versus vehicle controls.
Predicted outcome: ≥25% reduction in platform search latency during probe trial and ≥20% reduction in cortical Aβ42 ELISA levels versus vehicle.
Falsification: No significant improvement in spatial memory performance (p>0.05 between groups) or no reduction in cortical Aβ42 (<15% change) after 8-week treatment.
View on SciDEX ↗